The Bioprocess Validation Market size is projected to reach a CAGR of 5.9% from 2021 to 2028.
Bioprocess validation involves a series of activities taking place over the entire production cycle of a bio-product. An important part of bioprocess validation requires the evaluation of active pharmaceutical ingredients (APIs) and possible contaminants, such as mycoplasma, bacteria, endotoxin, and others, during the development and manufacture processes of animal drugs or other biological products. Precisely, data are collected, evaluated, and documented from every stage of a specific project at all desired levels. In this way, bioprocess validation establishes the scientific evidence that a process is capable of consistently delivering quality product. As a result, effective process validation contributes significantly to assure drug quality, safety, and efficacy.
Stringent safety and quality regulations governing product certification and testing across the biopharmaceutical and pharmaceutical industries, high demand for the outsourcing of bioprocess validation services, and regulatory mandates in the healthcare industry to maintain compliance with Good Manufacturing Practices (GMP) are some of the factors that have supported long-term expansion for Bioprocess Validation Market.
Asia-Pacific held the major share of the bioprocess validation market in 2019, and is expected to continue its dominance during the forecast period, owing to increase in biopharmaceutical manufacturing capabilities in Asia-Pacific countries, increase in demand for outsourcing bioprocess validation, rise in life science research specific to biologics, and surge in investments by pharmaceutical & biotechnology companies.
Insights are provided for each region and major countries within the regions
|
Report Feature |
Descriptions |
|---|---|
|
Growth Rate |
CAGR of 5.9% during the forecasting period, 2021-2028 |
|
Historical Data |
2018-2019 |
|
Forecast Years |
2021-2028 |
|
Base Year |
2020 |
|
Units Considered |
Revenue in USD billion and CAGR from 2021 to 2028 |
|
Report Segmentation |
type, technology and region. |
|
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
|
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East and Africa |
|
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe) |
|
Companies Profiled |
Cobetter Filtration Equipment Co., Ltd, Danher Corporation, Merck KGaA, Porvair Plc, Sartorius, Thermo Fisher Scientific, Inc., Meissner Filtration Products, Inc, Toxikon Corporation, Almac Group, and Biozeen. |
|
Available Customization |
In addition to the market data for Bioprocess Validation Market, Delvens offers client-centric report and customized according to the company’s specific demand and requirement. |
Bioprocess Validation Market is segmented into test type, process component, end user and region.
.png)
.png)
.png)
.png)
.png)
.png)